ONCONANO MEDICINE
OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue. OncoNano Medicine is a UTSW spinoff company based in Dallas, Texas.
ONCONANO MEDICINE
Industry:
Alternative Medicine Biotechnology Health Care Nanotechnology
Founded:
2014-12-29
Address:
Southlake, Texas, United States
Country:
United States
Website Url:
http://www.onconano.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
119.73 M USD
Technology used in webpage:
SPF GoDaddy DNS Google Google Cloud Mimecast
Similar Organizations
Homology Medicines
Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Ocean Biomedical
Ocean Biomedical is a biotechnology company that accelerates new discoveries in the world of medicine.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
Praxis Precision Medicines
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Current Employees Featured
Founder
Investors List
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Series B - Onconano Medicine
Adam Okun
Adam Okun investment in Series B - Onconano Medicine
Advantech Capital
Advantech Capital investment in Series B - Onconano Medicine
Salem Partners
Salem Partners investment in Series A - Onconano Medicine
Salem Partners
Salem Partners investment in Series A - Onconano Medicine
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Grant - Onconano Medicine
Key Employee Changes
Official Site Inspections
http://www.onconano.com Semrush global rank: 5.06 M Semrush visits lastest month: 1.63 K
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Onconano Medicine"
OncoNano
OncoNano Medicine to Present Late-Breaking Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024. April 2024. Contact Us. Headquarters OncoNano Medicine, Inc. 3060 Pegasus Park Dallas, Texas …See details»
ABOUT US - OncoNano
OncoNano Medicine was established to improve the lives of cancer patients. Our team of scientists, physicians and advisors is pioneering the next frontier of cancer therapeutics using our proprietary nanotechnology platform. …See details»
Onconano Medicine - Crunchbase Company Profile
OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets …See details»
OncoNano Medicine, Inc. | LinkedIn
OncoNano Medicine, Inc. | 1,766 followers on LinkedIn. OncoNano is harnessing the power of nanotechnology to unlock a new era of targeted therapeutics. Our ON-BOARDâ„¢ polymeric micelle platform ...See details»
OncoNano Medicine, Inc. - Drug pipelines, Patents, Clinical trials ...
OncoNano's ON-BOARDâ„¢ polymeric micelle platform is designed to leverage a universal tumor target, namely pH, to precisely deliver anti-cancer payloads to the tumor microenvironment. ...See details»
OncoNano Medicine - PitchBook
OncoNano Medicine has raised $104M. Who are OncoNano Medicine’s investors? Advantech Capital Partners , AG Collective Capital , CKG Management , Green Park & Golf Ventures , …See details»
Onconano Medicine Company Profile - Office Locations ... - Craft
OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise …See details»
Onconano Medicine - Funding, Financials, Valuation & Investors
OncoNano Medicine is a biotech company that develops pH-activated compounds that digitalize and exploit the variability of pH in disease. ... Solutions. Products. Resources. Pricing. …See details»
OncoNano Medicine Appoints Brett Giroir, M.D., to Board of …
Dec 17, 2021 Giroir also served as the U.S. Representative to the Executive Board of the World Health Organization within the Department of State, and was on the front lines of the COVID …See details»
Southlake BioTech Startup Gets $10M Grant from CPRIT for …
Aug 20, 2020 Southlake-based biotech startup OncoNano Medicine says it’s received a $9.97 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to expand …See details»
OncoNano Medicine Presents Preclinical Data for ON-BOARD™ IL …
SOUTHLAKE, Texas, April 10, 2024--OncoNano Medicine presented preclinical data for its ON-BOARDâ„¢ IL-12 program at the AACR Annual Meeting 2024. SOUTHLAKE, Texas, April 10, …See details»
OncoNano: New Approaches to Old Science - BioSpace
Mar 9, 2020 In late-August, OncoNano received a $15.4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance ONM-500. This was on top of …See details»
News — Press Releases — OncoNano
SOUTHLAKE, Texas – October 5, 2022 – OncoNano Medicine, Inc. today announced it will be presenting data on two development candidates, as well as its ON-BOARDâ„¢ delivery …See details»
OncoNano Medicine Announces Pre-Clinical Data for Dual …
Nov 10, 2022 ONM-501, OncoNano’s lead therapeutic program in development, is a dual-activating STING (Stimulator of Interferon Genes) agonist advancing towards a first in human …See details»
OncoNano Medicine Announces Expanded Research ... - Business …
Sep 22, 2021 OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit universal and immune targets for cancer …See details»
Press Releases - OncoNano
OncoNano Medicine Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD Platform at AACR 2022 Annual Meeting. Apr 12, 2022. Apr 12, 2022. Mar 11, …See details»
OncoNano Medicine Announces First Patient Dosed in Phase 1 …
SOUTHLAKE, Texas, November 27, 2023--OncoNano Medicine announced that the first patient has been dosed in its Phase 1 ONM-501 trial. SOUTHLAKE, Texas, November 27, 2023- …See details»
Press Releases - OncoNano
OncoNano Medicine to Present Late-Breaking Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024. SOUTHLAKE, Texas – March 6, 2024 – OncoNano …See details»
OncoNano Medicine Presents Positive Final Results from Phase 2 …
May 31, 2023 ONM-501, OncoNano’s second development program, is a next generation STING (STimulator of INterferon Genes) agonist that is advancing towards a first in human …See details»
TECHNOLOGY OVERVIEW - OncoNano
OncoNano’s ON-BOARDâ„¢ technology is designed to efficiently direct a wide variety of therapeutic payloads to the tumor microenvironment. ON-BOARDâ„¢ ultra pH-sensitive …See details»